Page last updated: 2024-11-04

sarpogrelate and Hypertension, Pulmonary

sarpogrelate has been researched along with Hypertension, Pulmonary in 6 studies

sarpogrelate: structure given in first source

Hypertension, Pulmonary: Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.

Research Excerpts

ExcerptRelevanceReference
"This study investigated whether sarpogrelate hydrochloride (SPG), a 5-HT2A receptor antagonist, alleviates chronic hypoxic pulmonary hypertension (CH-PH) in rats by stimulating apoptosis and inhibiting proliferation in pulmonary artery smooth muscle cells (PASMCs)."7.83The effects of the 5-HT2A receptor antagonist sarpogrelate hydrochloride on chronic hypoxic pulmonary hypertension in rats. ( Fan, FL; Geng, J; He, S; Liu, Y; Ma, Q; Meng, Y; Tian, H; Tian, HY; Zhang, D; Zhang, JB, 2016)
"The purpose of the present study was to determine if sarpogrelate hydrochloride (SPG), a serotonin 5HT2A receptor antagonist, prevented the development of chronic hypoxia-induced pulmonary hypertension (PH) and hypertensive pulmonary vascular remodeling."7.81Sarpogrelate hydrochloride, a serotonin 5HT2A receptor antagonist, ameliorates the development of chronic hypoxic pulmonary hypertension in rats. ( Ma, N; Maruyama, J; Maruyama, K; Mitani, Y; Nishikawa, M; Sawada, H; Yokochi, A; Zhang, E, 2015)
"The significance of serotonin in the pathogenesis of monocrotaline-induced pulmonary hypertension (MCT-PH) in rats, plasma serotonin concentrations, and the effect of a serotonin receptor antagonist administration in association with the number of proliferative cells were investigated."7.70Development of monocrotaline-induced pulmonary hypertension is attenuated by a serotonin receptor antagonist. ( Ito, M; Kasukawa, R; Miyata, M; Ohira, H; Sasajima, T; Sato, Y, 2000)
"This study investigated whether sarpogrelate hydrochloride (SPG), a 5-HT2A receptor antagonist, alleviates chronic hypoxic pulmonary hypertension (CH-PH) in rats by stimulating apoptosis and inhibiting proliferation in pulmonary artery smooth muscle cells (PASMCs)."3.83The effects of the 5-HT2A receptor antagonist sarpogrelate hydrochloride on chronic hypoxic pulmonary hypertension in rats. ( Fan, FL; Geng, J; He, S; Liu, Y; Ma, Q; Meng, Y; Tian, H; Tian, HY; Zhang, D; Zhang, JB, 2016)
"The purpose of the present study was to determine if sarpogrelate hydrochloride (SPG), a serotonin 5HT2A receptor antagonist, prevented the development of chronic hypoxia-induced pulmonary hypertension (PH) and hypertensive pulmonary vascular remodeling."3.81Sarpogrelate hydrochloride, a serotonin 5HT2A receptor antagonist, ameliorates the development of chronic hypoxic pulmonary hypertension in rats. ( Ma, N; Maruyama, J; Maruyama, K; Mitani, Y; Nishikawa, M; Sawada, H; Yokochi, A; Zhang, E, 2015)
"The significance of serotonin in the pathogenesis of monocrotaline-induced pulmonary hypertension (MCT-PH) in rats, plasma serotonin concentrations, and the effect of a serotonin receptor antagonist administration in association with the number of proliferative cells were investigated."3.70Development of monocrotaline-induced pulmonary hypertension is attenuated by a serotonin receptor antagonist. ( Ito, M; Kasukawa, R; Miyata, M; Ohira, H; Sasajima, T; Sato, Y, 2000)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (50.00)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Han, J1
Tian, H2
Liu, Y2
Fan, F1
Zhang, E1
Maruyama, J1
Yokochi, A1
Mitani, Y1
Sawada, H1
Nishikawa, M1
Ma, N1
Maruyama, K1
Geng, J1
Fan, FL1
He, S1
Meng, Y1
Zhang, D1
Ma, Q1
Zhang, JB1
Tian, HY1
Hironaka, E1
Hongo, M1
Sakai, A1
Mawatari, E1
Terasawa, F1
Okumura, N1
Yamazaki, A1
Ushiyama, Y1
Yazaki, Y1
Kinoshita, O1
Kawano, H1
Sengyoku, H1
Satoh, O1
Urabe, S1
Koide, Y1
Yano, K1
Miyata, M1
Ito, M1
Sasajima, T1
Ohira, H1
Sato, Y1
Kasukawa, R1

Other Studies

6 other studies available for sarpogrelate and Hypertension, Pulmonary

ArticleYear
Sarpogrelate attenuates pulmonary arterial hypertension via calcium/calcineurin axis.
    Frontiers in bioscience (Landmark edition), 2019, 01-01, Volume: 24, Issue:4

    Topics: Animals; Calcineurin; Calcium; Gene Expression; Hypertension, Pulmonary; Male; NFATC Transcription F

2019
Sarpogrelate hydrochloride, a serotonin 5HT2A receptor antagonist, ameliorates the development of chronic hypoxic pulmonary hypertension in rats.
    Journal of anesthesia, 2015, Volume: 29, Issue:5

    Topics: Animals; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Hypoxia; Lung; Male; Nitric Oxide

2015
The effects of the 5-HT2A receptor antagonist sarpogrelate hydrochloride on chronic hypoxic pulmonary hypertension in rats.
    Experimental lung research, 2016, Volume: 42, Issue:4

    Topics: Animals; Apoptosis; Cell Proliferation; Chronic Disease; Hypertension, Pulmonary; Hypoxia; Male; Myo

2016
Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats.
    Cardiovascular research, 2003, Dec-01, Volume: 60, Issue:3

    Topics: Animals; Endothelium, Vascular; Hypertension, Pulmonary; Lung; Male; Monocrotaline; Nitric Oxide Syn

2003
Marked improvement with sildenafil in a patient with idiopathic pulmonary arterial hypertension unresponsive to beraprost and sarpogrelate.
    Internal medicine (Tokyo, Japan), 2007, Volume: 46, Issue:12

    Topics: Adolescent; Drug Therapy, Combination; Epoprostenol; Humans; Hypertension, Pulmonary; Male; Piperazi

2007
Development of monocrotaline-induced pulmonary hypertension is attenuated by a serotonin receptor antagonist.
    Lung, 2000, Volume: 178, Issue:2

    Topics: Animals; Cell Division; Endothelium, Vascular; Hypertension, Pulmonary; Male; Monocrotaline; Prolife

2000